4.4 Article

Effects of Collection and Processing Procedures on Plasma Circulating Cell-Free DNA from Cancer Patients

期刊

JOURNAL OF MOLECULAR DIAGNOSTICS
卷 20, 期 6, 页码 883-892

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jmoldx.2018.07.005

关键词

-

资金

  1. NIHR Cambridge Biomedical Research Center

向作者/读者索取更多资源

Circulating tumor DNA (ctDNA) offers new opportunities for noninvasive cancer management. Detecting ctDNA in plasma is challenging because it constitutes only a minor fraction of the total cell-free DNA (cfDNA). Pre-analytical factors affect cfDNA levels contributed from leukocyte lysis, hence the ability to detect low frequency mutant alleles. This study investigates the effects of the delay in processing, storage temperatures, different blood collection tubes, centrifugation protocols, and sample shipment on cfDNA levels. Peripheral blood (n = 231) from cancer patients (n = 62) were collected into K(3)EDTA or Cell-free DNA BCT tubes and analyzed by digital PCR, targeted amplicon, or shallow whole-genome sequencing. To assess pre-analytic effects, plasma was processed under different conditions after 0, 6, 24, 48, 96 hours, and 1 week at room temperature or 4 degrees C, or using different centrifugation protocols. Digital PCR showed that cfDNA levels increased gradually with time in K3EDTA tubes, but were stable in BCT tubes. K(3)EDTA samples stored at 4 degrees C showed less variation than room temperature storage, but levels were elevated compared with BCT. A second centrifugation at 3000 x g gave similar cfDNA yields compared with higher-speed centrifugation. Next-generation sequencing showed negligible differences in background error or copy number changes between K(3)EDTA and BCT, or following shipment in BCT. This study provides insights into the effects of sample processing on ctDNA analysis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Copy number heterogeneity identifies ER plus breast cancer patients that do not benefit from adjuvant endocrine therapy

Tom van den Bosch, Oscar M. Rueda, Carlos Caldas, Louis Vermeulen, Daniel M. Miedema

Summary: This study found that low-risk breast cancer patients identified using chromosomal copy-number ITH do not benefit from adjuvant endocrine therapy.

BRITISH JOURNAL OF CANCER (2022)

Article Oncology

Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study

Ashley Weir, Eun-Young Kang, Nicola S. Meagher, Gregg S. Nelson, Prafull Ghatage, Cheng-Han Lee, Marjorie J. Riggan, Aleksandra Gentry-Maharaj, Andy Ryan, Naveena Singh, Martin Widschwendter, Jennifer Alsop, Michael S. Anglesio, Matthias W. Beckmann, Jessica Berger, Christiani Bisinotto, Jessica Boros, Alison H. Brand, James D. Brenton, Angela Brooks-Wilson, Michael E. Carney, Julie M. Cunningham, Kara L. Cushing-Haugen, Cezary Cybulski, Esther Elishaev, Ramona Erber, Sian Fereday, Anna Fischer, Luis Paz-Ares, Javier Gayarre, Blake C. Gilks, Marcel Grube, Paul R. Harnett, Holly R. Harris, Arndt Hartmann, Alexander Hein, Joy Hendley, Brenda Y. Hernandez, Sabine Heublein, Yajue Huang, Tomasz Huzarski, Anna Jakubowska, Mercedes Jimenez-Linan, Catherine J. Kennedy, Felix K. F. Kommoss, Jennifer M. Koziak, Bernhard Kraemer, Nhu D. Le, Jaime Lesnock, Jenny Lester, Jan Lubinski, Janusz Menkiszak, Britta Ney, Alexander Olawaiye, Sandra Orsulic, Ana Osorio, Luis Robles-Diaz, Matthias Ruebner, Mitul Shah, Raghwa Sharma, Yurii B. Shvetsov, Helen Steed, Aline Talhouk, Sarah E. Taylor, Nadia Traficante, Robert A. Vierkant, Chen Wang, Lynne R. Wilkens, Stacey J. Winham, Javier Benitez, Andrew Berchuck, David D. Bowtell, Francisco J. Candido dos Reis, Linda S. Cook, Anna DeFazio, Jennifer A. Doherty, Peter A. Fasching, Maria J. Garcia, Ellen L. Goode, Marc T. Goodman, Jacek Gronwald, David G. Huntsman, Beth Y. Karlan, Stefan Kommoss, Francesmary Modugno, Joellen M. Schildkraut, Hans-Peter Sinn, Annette Staebler, Linda E. Kelemen, Caroline E. Ford, Usha Menon, Paul D. P. Pharoah, Martin Koebel, Susan J. Ramus, D. Bowtell, A. DeFazio, N. Traficante, S. Fereday, A. Brand, P. Harnett, R. Sharma

Summary: Recently, a study found a positive correlation between protein expression of FOXJ1 and the 5-year survival rate of patients with tubo-ovarian high-grade serous carcinoma (HGSC). However, protein expression of GMNN was not significantly associated with patient survival. This study provides preliminary evidence for the prognostic value of FOXJ1 in HGSC and validates the prior mRNA-based prognostic association through immunohistochemistry.

BRITISH JOURNAL OF CANCER (2023)

Article Oncology

CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study

Eun-Young Kang, Ashley Weir, Nicola S. Meagher, Kyo Farrington, Gregg S. Nelson, Prafull Ghatage, Cheng-Han Lee, Marjorie J. Riggan, Adelyn Bolithon, Gordana Popovic, Betty Leung, Katrina Tang, Neil Lambie, Joshua Millstein, Jennifer Alsop, Michael S. Anglesio, Beyhan Ataseven, Ellen Barlow, Matthias W. Beckmann, Jessica Berger, Christiani Bisinotto, Hans Boesmueller, Jessica Boros, Alison H. Brand, Angela Brooks-Wilson, Sara Y. Brucker, Michael E. Carney, Yovanni Casablanca, Alicia Cazorla-Jimenez, Paul A. Cohen, Thomas P. Conrads, Linda S. Cook, Penny Coulson, Madeleine Courtney-Brooks, Daniel W. Cramer, Philip Crowe, Julie M. Cunningham, Cezary Cybulski, Kathleen M. Darcy, Mona A. El-Bahrawy, Esther Elishaev, Ramona Erber, Rhonda Farrell, Sian Fereday, Anna Fischer, Maria J. Garcia, Simon A. Gayther, Aleksandra Gentry-Maharaj, C. Blake Gilks, Marcel Grube, Paul R. Harnett, Shariska Petersen Harrington, Philipp Harter, Arndt Hartmann, Jonathan L. Hecht, Sebastian Heikaus, Alexander Hein, Florian Heitz, Joy Hendley, Brenda Y. Hernandez, Susanna Hernando Polo, Sabine Heublein, Akira Hirasawa, Estrid Hogdall, Claus K. Hogdall, Hugo M. Horlings, David G. Huntsman, Tomasz Huzarski, Andrea Jewell, Mercedes Jimenez-Linan, Michael E. Jones, Scott H. Kaufmann, Catherine J. Kennedy, Dineo Khabele, Felix K. F. Kommoss, Roy F. P. M. Kruitwagen, Diether Lambrechts, Nhu D. Le, Marcin Lener, Jenny Lester, Yee Leung, Anna Linder, Liselore Loverix, Jan Lubinski, Rashna Madan, G. Larry Maxwell, Francesmary Modugno, Susan L. Neuhausen, Alexander Olawaiye, Siel Olbrecht, Sandra Orsulic, Jose Palacios, Celeste Leigh Pearce, Malcolm C. Pike, Carmel M. Quinn, Ganendra Raj Mohan, Cristina Rodriguez-Antona, Matthias Ruebner, Andy Ryan, Stuart G. Salfinger, Naoko Sasamoto, Joellen M. Schildkraut, Minouk J. Schoemaker, Mitul Shah, Raghwa Sharma, Yurii B. Shvetsov, Naveena Singh, Gabe S. Sonke, Linda Steele, Colin J. R. Stewart, Karin Sundfeldt, Anthony J. Swerdlow, Aline Talhouk, Adeline Tan, Sarah E. Taylor, Kathryn L. Terry, Aleksandra Toloczko, Nadia Traficante, Koen K. Van de Vijver, Maaike A. van der Aa, Toon Van Gorp, Els Van Nieuwenhuysen, Lilian Van-Wagensveld, Ignace Vergote, Robert A. Vierkant, Chen Wang, Lynne R. Wilkens, Stacey J. Winham, Anna H. Wu, Javier Benitez, Andrew Berchuck, Francisco J. Candido Dos Reis, Anna DeFazio, Peter A. Fasching, Ellen L. Goode, Marc T. Goodman, Jacek Gronwald, Beth Y. Karlan, Stefan Kommoss, Usha Menon, Hans-Peter Sinn, Annette Staebler, James D. Brenton, David D. Bowtell, Paul D. P. Pharoah, Susan J. Ramus, Martin Kobel

Summary: This study validates that high-level amplification of CCNE1 is associated with shorter survival in tubo-ovarian high-grade serous carcinoma (HGSC), supporting its use as a prognostic biomarker in this disease.

CANCER (2023)

Article Oncology

Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery

Minh Tung Phung, Penelope M. Webb, Anna DeFazio, Sian Fereday, Alice W. Lee, David D. L. Bowtell, Peter A. Fasching, Ellen L. Goode, Marc T. Goodman, Beth Y. Karlan, Jenny Lester, Keitaro Matsuo, Francesmary Modugno, James D. Brenton, Toon Van Gorp, Paul D. P. Pharoah, Joellen M. Schildkraut, Karen McLean, Rafael Meza, Bhramar Mukherjee, Jean Richardson, Bronwyn Grout, Anne Chase, Cindy McKinnon Deurloo, Kathryn L. Terry, Gillian E. Hanley, Malcolm C. Pike, Andrew Berchuck, Susan J. Ramus, Celeste Leigh Pearce, Ovarian Canc Assoc Consortium

Summary: This study analyzed the association between 12 lifestyle and personal exposures and having residual disease after surgery in patients with high-grade serous ovarian cancer (HGSC). The use of menopausal estrogen-only therapy (ET) was associated with a lower likelihood of having macroscopic residual disease, while parous women who did not breastfeed also had a lower likelihood of residual disease. These factors could potentially be included in risk stratification models for HGSC patients.

GYNECOLOGIC ONCOLOGY (2023)

Article Oncology

Profiling the immune landscape in mucinous ovarian carcinoma

Nicola S. Meagher, Phineas Hamilton, Katy Milne, Shelby Thornton, Bronwyn Harris, Ashley Weir, Jennifer Alsop, Christiani Bisinoto, James D. Brenton, Angela Brooks-Wilsoni, Derek S. Chiu, Kara L. Cushing-Haugen, Sian Fereday, Dale W. Garsed, Simon A. Gayther, Aleksandra Gentry-Maharaj, Blake Gilks, Mercedes Jimenez-Linan, Catherine J. Kennedy, Nhu D. Le, Anna M. Piskorz, Marjorie J. Riggan, Mitul Shah, Naveena Singh, Aline Talhoukj, Martin Widschwendter, David D. L. Bowtell, Francisco J. Candido dos Reis, Linda S. Cook, Renee T. Fortner, Maria J. Garcia, Holly R. Harris, David G. Huntsman, Anthony N. Karnezis, Martin Kobel, Usha Menon, Paul D. P. Pharoah, Jennifer A. Doherty, Michael S. Anglesioj, Malcolm C. Pike, Celeste Leigh Pearce, Michael L. Friedlander, Anna DeFazio, Brad H. Nelson, Susan J. Ramus

Summary: This study conducted immunohistochemistry and immunofluorescence on 126 patients with mucinous ovarian carcinoma (MOC) and found that MOCs are mainly characterized by high densities of immune suppressor cells in the tumor epithelium, suggesting limited response to current immunotherapies.

GYNECOLOGIC ONCOLOGY (2023)

Review Immunology

Multiparameter single-cell proteomic technologies give new insights into the biology of ovarian tumors

Funingana Ionut-Gabriel, Jacob S. Bedia, Ying-Wen Huang, Antonio Delgado Gonzalez, Kenyi Donoso, Veronica D. Gonzalez, James D. Brenton, Alan Ashworth, Wendy J. Fantl

Summary: High-grade serous ovarian cancer (HGSOC) is a challenging gynecological malignancy due to its advanced stage diagnosis, diverse carboplatin resistance mechanisms, and lack of response to immunotherapy. Multiplex single-cell proteomic technologies could provide insights into the functional interplay between cell autonomous responses to carboplatin and the HGSOC immune tumor microenvironment. This review suggests that the incorporation of multiplex single-cell proteomic technologies into biomarker development, along with genomics and radiomics, could improve clinical care for HGSOC patients.

SEMINARS IN IMMUNOPATHOLOGY (2023)

Article Oncology

Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2

Denise G. O'Mahony, Susan J. Ramus, Melissa C. Southey, Nicola S. Meagher, Andreas Hadjisavvas, Esther M. John, Ute Hamann, Evgeny N. Imyanitov, Irene L. Andrulis, Priyanka Sharma, Mary B. Daly, Christopher R. Hake, Jeffrey N. Weitzel, Anna Jakubowska, Andrew K. Godwin, Adalgeir Arason, Anita Bane, Jacques Simard, Penny Soucy, Maria A. Caligo, Phuong L. Mai, Kathleen B. M. Claes, Manuel R. Teixeira, Wendy K. Chung, Conxi Lazaro, Peter J. Hulick, Amanda E. Toland, Inge Sokilde Pedersen, Susan L. Neuhausen, Ana Vega, Miguel de la Hoya, Heli Nevanlinna, Mallika Dhawan, Valentina Zampiga, Rita Danesi, Liliana Varesco, Viviana Gismondi, Valerio Gaetano Vellone, Paul A. James, Ramunas Janavicius, Liene Nikitina-Zake, Finn Cilius Nielsen, Thomas van Overeem Hansen, Tanja Pejovic, Ake Borg, Johanna Rantala, Kenneth Offit, Marco Montagna, Katherine L. Nathanson, Susan M. Domchek, Ana Osorio, Maria J. Garcia, Beth Y. Karlan, Anna De Fazio, David Bowtell, Lesley McGuffog, Goska Leslie, Michael T. Parsons, Thilo Doerk, Lisa-Marie Speith, Elizabeth Santana dos Santos, Alexandre Andre B. A. da Costa, Paolo Radice, Paolo Peterlongo, Laura Papi, Christoph Engel, Eric Hahnen, Rita K. Schmutzler, Barbara Wappenschmidt, Douglas F. Easton, Marc Tischkowitz, Christian F. Singer, Yen Yen Tan, Alice S. Whittemore, Weiva Sieh, James D. Brenton, Drakoulis Yannoukakos, Florentia Fostira, Irene Konstantopoulou, Jana Soukupova, Michal Vocka, Georgia Chenevix-Trench, Paul D. P. Pharoah, Antonis C. Antoniou, David E. Goldgar, Amanda B. Spurdle, Kyriaki Michailidou, Marian J. E. Mourits, Fabienne Lesueur

Summary: This study assessed the utility of ovarian tumour characteristics as predictors of BRCA1 and BRCA2 variant pathogenicity and provided evidence for improved classification and clinical management of carriers.

BRITISH JOURNAL OF CANCER (2023)

Article Oncology

Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study

Robert D. Morgan, Andrew R. Clamp, Bethany M. Barnes, Kirsten Timms, Helene Schlecht, Laura Yarram-Smith, Yvonne Wallis, Mikel Valganon-Petrizan, Suzanne MacMahon, Rhian White, Sian Morgan, Sarah McKenna, Emma Hudson, Laura Tookman, Angela George, Ranjit Manchanda, Sudha S. Sundar, Shibani Nicum, James D. Brenton, Rebecca S. Kristeleit, Susana Banerjee, Iain A. McNeish, Jonathan A. Ledermann, Stephen S. Taylor, D. Gareth R. Evans, Gordon C. Jayson

Summary: This study reports data from the first year of routine homologous recombination deficiency testing in the NHS in England, Wales, and Northern Ireland, demonstrating the significant survival benefits of olaparib plus bevacizumab maintenance therapy in women with newly diagnosed, advanced, high-grade ovarian cancer.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2023)

Article Biochemistry & Molecular Biology

Positional influence on cellular transcriptional identity revealed through spatially segmented single-cell transcriptomics

David B. Morse, Aleksandra M. Michalowski, Michele Ceribelli, Joachim De Jonghe, Maria Vias, Deanna Riley, Theresa Davies-Hill, Ty Voss, Stefania Pittaluga, Christoph Muus, Jiamin Liu, Samantha Boyle, David A. Weitz, James D. Brenton, Jason D. Buenrostro, Tuomas P. J. Knowles, Craig J. Thomas

Summary: Single-cell RNA sequencing (scRNA-seq) is used to describe cell states, but the spatial arrangement of these states in tissues is challenging. Segmentation by exogenous perfusion (SEEP) is a method that links surface proximity and environment accessibility to transcriptional identity within 3D disease models. Using SEEP, analysis of ovarian cancer models reveals the relationship between cell state and position, and shows how microenvironments influence individual cell identities.

CELL SYSTEMS (2023)

Article Oncology

Lesion-specific 3D-printed moulds for image-guided tissue multi-sampling of ovarian tumours: A prospective pilot study

Maria Delgado-Ortet, Marika A. V. Reinius, Cathal McCague, Vlad Bura, Ramona Woitek, Leonardo Rundo, Andrew B. Gill, Marcel Gehrung, Stephan Ursprung, Helen Bolton, Krishnayan Haldar, Pubudu Pathiraja, James D. Brenton, Mireia Crispin-Ortuzar, Mercedes Jimenez-Linan, Lorena Escudero Sanchez, Evis Sala

Summary: In this study, a research pathway and automated computational pipeline were developed to create lesion-specific 3D-printed moulds based on preoperative imaging, allowing for detailed spatial correlation between imaging and tissue-derived data. This method can guide comprehensive multi-sampling of various pelvic tumors.

FRONTIERS IN ONCOLOGY (2023)

Article Biology

Calibrating ensembles for scalable uncertainty quantification in deep learning-based medical image segmentation

Thomas Buddenkotte, Lorena Escudero Sanchez, Mireia Crispin-Ortuzar, Ramona Woitek, Cathal McCague, James D. Brenton, Ozan Oktem, Evis Sala, Leonardo Rundo

Summary: Uncertainty quantification is highly desired in automated image analysis. Current approaches fail to scale well in high-dimensional real-world problems. We propose a scalable framework that approximates classification probability and suggest the usage of k-fold cross-validation to overcome the need for calibration data. Our method can be adopted in active learning and human-machine collaboration.

COMPUTERS IN BIOLOGY AND MEDICINE (2023)

Article Multidisciplinary Sciences

The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma

Philip Smith, Thomas Bradley, Lena Morrill Gavarro, Teodora Goranova, Darren P. Ennis, Hasan B. Mirza, Dilrini De Silva, Anna M. Piskorz, Carolyn Sauer, Sarwah Al-Khalidi, Ionat-Gabriel Funingana, Marika A. V. Reinius, Gaia Giannone, Liz-Anne Lewsley, Jamie Stobo, John McQueen, Gareth Bryson, Matthew Eldridge, R. M. Glasspool, C. Gourley, R. Kennedy, G. Hall, R. Edmondson, A. Clamp, S. Sundar, A. Walter, M. Hall, H. Gabra, C. Fotopoulou, E. Brockbank, A. Montes, M. Lockley, Geoff Macintyre, Florian Markowetz, James D. Brenton, Iain A. McNeish

Summary: Treatment resistance is common in ovarian high grade serous carcinoma, often leading to relapse. Here, the authors leverage shallow whole genome and panel sequencing of 276 patients with available diagnostic and relapse samples and show high concordance of copy number and mutation status.

NATURE COMMUNICATIONS (2023)

Article Oncology

Identification of Tissue-Resident Natural Killer and T Lymphocytes with Anti-Tumor Properties in Ascites of Ovarian Cancer Patients

Elin Bernson, Oisin Huhn, Veronika Karlsson, Delia Hawkes, Maria Lycke, Valentina Cazzetta, Joanna Mikulak, James Hall, Anna M. Piskorz, Rosalba Portuesi, Domenico Vitobello, Barbara Fiamengo, Gabriele Siesto, Amir Horowitz, Hormas Ghadially, Domenico Mavilio, James D. Brenton, Karin Sundfeldt, Francesco Colucci

Summary: Ovarian cancer, the deadliest among gynecological cancers, requires new treatment options. Immunotherapy shows great potential but has not yet been successful for most ovarian cancer patients. By studying lymphocytes in high-grade serous ovarian cancer patients, we found the presence of natural killer cells and T cells in primary tumors and ascites. These cells express tissue-resident markers and the inhibitory receptor, NKG2A, and can kill ovarian cancer cells. In summary, we report a functional subset of lymphocytes that may be targeted in future immunotherapeutic approaches.

CANCERS (2023)

Article Multidisciplinary Sciences

Obesity-associated changes in molecular biology of primary breast cancer

Ha-Linh Nguyen, Tatjana Geukens, Marion Maetens, Samuel Aparicio, Ayse Bassez, Ake Borg, Jane Brock, Annegien Broeks, Carlos Caldas, Fatima Cardoso, Maxim De Schepper, Mauro Delorenzi, Caroline A. Drukker, Annuska M. Glas, Andrew R. Green, Edoardo Isnaldi, Jorunn Eyfjoro, Hazem Khout, Stian Knappskog, Savitri Krishnamurthy, Sunil R. Lakhani, Anita Langerod, John W. M. Martens, Amy E. McCart Reed, Leigh Murphy, Stefan Naulaerts, Serena Nik-Zainal, Ines Nevelsteen, Patrick Neven, Martine Piccart, Coralie Poncet, Kevin Punie, Colin Purdie, Emad A. Rakha, Andrea Richardson, Emiel Rutgers, Anne Vincent-Salomon, Peter T. Simpson, Marjanka K. Schmidt, Christos Sotiriou, Paul N. Span, Kiat Tee Benita Tan, Alastair Thompson, Stefania Tommasi, Karen Van Baelen, Marc Van de Vijver, Steven Van Laere, Laura van't Veer, Giuseppe Viale, Alain Viari, Hanne Vos, Anke T. Witteveen, Hans Wildiers, Giuseppe Floris, Abhishek D. Garg, Ann Smeets, Diether Lambrechts, Elia Biganzoli, Francois Richard, Christine Desmedt

Summary: Obesity is associated with an increased risk of developing breast cancer and worse prognosis in breast cancer patients. This study investigates the biological differences in untreated primary breast cancer according to patients' body mass index (BMI). The study finds several genomic alterations that are differentially prevalent in overweight or obese patients compared to lean patients. It also reveals an elevated and unresolved inflammation of the breast cancer tumor microenvironment associated with obesity. The findings suggest that patient adiposity may play a significant role in the heterogeneity of breast cancer and should be considered for tailored treatment.

NATURE COMMUNICATIONS (2023)

Article Oncology

Implementation of Whole-Genome and Transcriptome Sequencing Into Clinical Cancer Care

Edwin Cuppen, Olivier Elemento, Richard Rosenquist, Svetlana Nikic, Maarten IJzerman, Isabelle Durand Zaleski, Geert Frederix, Lars-Ake Levin, Charles G. Mullighan, Reinhard Buettner, Trevor J. Pugh, Sean Grimmond, Carlos Caldas, Fabrice Andre, Ilse Custers, Elias Campo, Hans van Snellenberg, Anna Schuh, Hidewaki Nakagawa, Christof von Kalle, Torsten Haferlach, Stefan Froehling, Vaidehi Jobanputra

Summary: The combination of whole-genome and transcriptome sequencing (WGTS) is a comprehensive precision diagnostic test that is expected to transform diagnosis and treatment for cancer patients. However, there are barriers to the implementation and widespread adoption of this test, including considerations of utility in different cancer types, cost-effectiveness and affordability.

JCO PRECISION ONCOLOGY (2022)

暂无数据